Browsing Tag
Sabeen Mekan
1 post
Zymeworks (ZYME) reports 64.5% ovarian cancer response rate for ZW191 as lower dose strengthens case
Zymeworks has reported encouraging Phase 1 results for its folate receptor alpha-targeting antibody-drug conjugate ZW191, including responses in ovarian tumors with low receptor expression and a more favorable safety profile at the lower tested dose.